Skip to content
lifestyle.latabloid.com/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Aktis Oncology Inc.
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
October 7, 2026
Aktis Oncology to Present at Upcoming September Investor Conferences
September 9, 2026
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
August 17, 2026
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
May 22, 2026
Aktis Oncology to Present at the BofA Securities Health Care Conference
May 21, 2026
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
May 21, 2026
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 21, 2026
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
April 16, 2026
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
March 30, 2026